New IgG and IgA autoantibody specificities against DNA-binding and RNA-binding proteins discriminate systemic lupus erythematosus from health and non-lupus autoimmunity-could anti-LIN28A enhance precision in diagnostics?Show others and affiliations
2025 (English)In: Annals of the Rheumatic Diseases, ISSN 0003-4967, E-ISSN 1468-2060, Vol. 84, no 7, p. 1180-1194Article in journal (Refereed) Published
Abstract [en]
OBJECTIVES: In response to the urgent unmet needs of heterogeneity, unpredictability, and diagnostic delay in systemic lupus erythematosus (SLE), we aimed to identify and validate new immunoglobulin (Ig)G and IgA autoantibody specificities.
METHODS: Using a KoRectly EXpressed technology-based microarrays (i-Ome Discovery; Sengenics), we screened for circulating IgG and IgA autoantibodies against 1609 proteins in 2 independent cohorts (discovery: NTC02890121; validation: NCT02890134) comprising patients with SLE (n = 199 and n = 30), primary Sjögren's disease (n = 115 and n = 31), and systemic sclerosis (n = 115 and n = 24), and healthy controls (HCs; n = 111 and n = 84), respectively.
RESULTS: We identified and validated 5 IgG (anti-Lin-28 homolog A [LIN28A], anti-HNRNPA2B1, anti-HMG20B, anti-HMGB2, and anti-alpha-globin transcription factor CP2 [TFCP2]) and 4 IgA (anti-LIN28A, anti-HMG20B, anti-SUB1, and anti-TFCP2) autoantibodies that demonstrated high specificity for SLE (0.91-0.94), along with consistent and robust positivity (0.22-0.69) in differentially abundant autoantibody (daAAb) analysis between SLE and comparator groups. IgG and IgA anti-LIN28A levels varied over a 14-month follow-up in the validation cohort of newly diagnosed patients with SLE and exhibited metrics that outperformed those of traditional autoantibody markers such as anti-double-stranded DNA. Clustering of patients with SLE based on autoantibody positivity (levels above the HC median plus 2 IQRs in the discovery cohort) status revealed 1 subgroup demonstrating seroreactivity against multiple antigens, 3 exhibiting varying reactivity, and 1 showing no reactivity. In pathway analysis, daAAb targets pointed to DNA-binding and RNA-binding and transcription functions.
CONCLUSIONS: Novel autoantibodies validated in this study may enhance diagnostics and molecular characterisation in SLE. The prominent IgA seroreactivity implicates important roles of mucosal tissues in SLE autoimmunity, warranting further investigation.
Place, publisher, year, edition, pages
Highwire Press , 2025. Vol. 84, no 7, p. 1180-1194
National Category
Rheumatology
Identifiers
URN: urn:nbn:se:oru:diva-121110DOI: 10.1016/j.ard.2025.04.003ISI: 001529794300009PubMedID: 40374430Scopus ID: 2-s2.0-105005503676OAI: oai:DiVA.org:oru-121110DiVA, id: diva2:1959137
Funder
Swedish Rheumatism Association, R-995882Stiftelsen Konung Gustaf V:s 80-årsfond, FAI-2023-1055Swedish Society of Medicine, SLS-974449Nyckelfonden, OLL-1000881Stiftelsen Ulla och Roland Gustafssons Donationsfond, 2024-43Region Stockholm, FoUI-1004114Karolinska InstituteSwedish Rheumatism Association, R-995557Stiftelsen Konung Gustaf V:s 80-årsfond, FAI-2023-1006Stiftelsen Ulla och Roland Gustafssons Donationsfond, 2024-49NyckelfondenNyckelfonden, 20200017EU, Horizon 2020
Note
Funding Agencies:
IP has received grants from the Swedish Rheumatism Association [R-995882], King Gustaf V’s 80-year Foundation [FAI-2023-1055], Swedish Society of Medicine [SLS-974449], Nyckelfonden [OLL-1000881], Professor Nanna Svartz Foundation [2021-00436], Ulla and Roland Gustafsson Foundation [2024-43], Region Stockholm [FoUI-1004114], and Karolinska Institutet. HI has received grants from the Swedish Rheumatism Association [R-939667]. DN has received grants from the Swedish Rheumatism Association [R-995557], King Gustaf V’s 80-year Foundation [FAI-2023-1006], Ulla and Roland Gustafsson Foundation [2024-49], Ulla and Gustaf af Uggla Foundation [2023-025029], and Karolinska Institutet. We acknowledge scientific support from the Exploring Inflammation in Health and Disease (X-HiDE) Consortium, a research profile at Örebro University funded by the Knowledge Foundation [grant 20200017]. This work was supported by Innovative Medicines Initiative (IMI) Joint Undertaking (JU) for the PRECISESADS project [grant 115565]. It also received funding from the IMI 2 JU for the Taxonomy, Treatment, Targets and Remission (3TR) project [grant 831434]. The JU receives support from the European Union’s Horizon 2020 research and innovation programme and European Federation of Pharmaceutical Industries and Associations (EFPIA).
2025-05-192025-05-192026-01-23Bibliographically approved